<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:department>Biochemistry</gtr:department><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/41310951-F67E-4AED-8141-ABDD49C6046D"><gtr:id>41310951-F67E-4AED-8141-ABDD49C6046D</gtr:id><gtr:name>Waters Corporation (USA)</gtr:name><gtr:address><gtr:line1>34 Maple Street</gtr:line1><gtr:line2>Milford</gtr:line2><gtr:line3>Ma01757-3696</gtr:line3><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5B9542CC-D7F0-45DA-A423-16458386EA25"><gtr:id>5B9542CC-D7F0-45DA-A423-16458386EA25</gtr:id><gtr:name>GlaxoSmithKline PLC</gtr:name><gtr:address><gtr:line1>Park Road</gtr:line1><gtr:postCode>SG12 0DP</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/7B37377E-AAF0-4C32-BA3D-0395632DCBB7"><gtr:id>7B37377E-AAF0-4C32-BA3D-0395632DCBB7</gtr:id><gtr:firstName>Julian</gtr:firstName><gtr:otherNames>Leether</gtr:otherNames><gtr:surname>Griffin</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/488C2FCA-F5F6-42C3-AA92-60939413CC24"><gtr:id>488C2FCA-F5F6-42C3-AA92-60939413CC24</gtr:id><gtr:firstName>Kathryn</gtr:firstName><gtr:otherNames>Susan</gtr:otherNames><gtr:surname>Lilley</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/521E032C-C065-41B2-9CEA-9A06C8BC5312"><gtr:id>521E032C-C065-41B2-9CEA-9A06C8BC5312</gtr:id><gtr:firstName>Antonio</gtr:firstName><gtr:surname>Vidal-Puig</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/D8BFDE50-0165-4235-8DE2-8664A2E5BF4D"><gtr:id>D8BFDE50-0165-4235-8DE2-8664A2E5BF4D</gtr:id><gtr:firstName>Andrew</gtr:firstName><gtr:otherNames>James</gtr:otherNames><gtr:surname>Murray</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=BB%2FH013539%2F1"><gtr:id>DECBA19C-8EC0-42AB-A871-82435C388F46</gtr:id><gtr:title>Burning fat: an in vivo and in vitro study of the role of PPAR-delta in regulating fat metabolism in adipose tissue</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>BB/H013539/1</gtr:grantReference><gtr:abstractText>People in the UK are getting fatter and this has consequences for both the health and wealth of the nation. Obesity increases the risk of a number of diseases including type 2 diabetes, heart disease, stroke and high blood pressure. These diseases will place an increasing burden on the National Health Service and also impair the ability of individuals to work. Central to this problem is energy balance which put basically is the difference between energy coming in as food and energy expenditure of the body. While one obvious solution is to reduce intake of high calorie foods and increase exercise in individuals, national strategies in this area have failed to halt the increase in obesity (or indeed slow the rate of increase). Furthermore, once an individual is obese it may be difficult for that person to exercise and reduce obesity. There are indications that drugs that increase the energy expenditure of the body may be used to reduce obesity and many of the risk factors for other diseases associated with obesity (e.g. insulin resistance, coronary artery disease). Several types of drugs target two proteins found in fat cells referred to as PPAR-gamma and PPAR-delta. These proteins in turn 'switch-on' genes important in either fat metabolism or fat storage. While a large amount of work has been carried out characterising PPAR-gamma, a known target for treating type II diabetes, relatively little work has been performed on PPAR-delta. This proposal sets out to investigate the role that these two receptors play in energy balance in fat cells using a combination of animal studies and in vitro cell culture. For this we will investigate the action of two drugs that target either PPAR-gamma or PPAR-delta in adipose tissue in mice and investigate how they alter the concentration of key metabolites using mass spectrometry and Nuclear Magnetic Resonance (NMR) spectroscopy, gene expression using DNA microarrays and protein content by mass spectrometry based proteomics. The data collected will then be modelled mathematically by statistics to generate hypotheses which can be pursued in cell culture based experiments. The latter approach allows us to manipulate the system more easily and hence probe mechanisms of action. This work will increase our knowledge of the mechanisms controlling energy balance in fat cells and also allow us to develop an experimental approach which could be used to understand other biochemical processes. In addition the information obtained will help better characterise a major potential drug target for obesity and associated complications.</gtr:abstractText><gtr:technicalSummary>PPAR-delta is a receptor that is highly expressed in adipose tissue, and has been shown to be a potent target for the treatment of obesity. However, to date relatively little work has been carried out on this receptor compared with the other members of the PPAR family, PPAR-alpha and PPAR-gamma, both targets for current treatments of type II diabetes and aspects of the metabolic syndrome. PPAR-delta plays a major role in regulating the transition between fatty acid storage and fatty acid oxidation. Understanding the processes that allow the switch between storage and catabolism of fatty acids in adipose is one of the great challenges in understanding lipid metabolism within the body. This proposal describes a systems biology study of the action of PPAR-delta agonists in adipocytes, making use of a combined in vivo and in vitro approach using a combination of metabolomics, stable isotope analysis, transcriptomics and proteomics. The proposal will examine the metabolic consequences of administrating PPAR-delta, PPAR-gamma and PPARpan (targeting both PPAR-delta and PPAR-gamma) agonists to adipose tissue, examining both acute and chronic (two year) studies in mice using our poly-omic approach. Data fusion will be performed using a variety of multivariate statistics and the use of pathway analysis tools. Key metabolic changes will then be modelled in vitro in cell culture of 3T3-L1 cells using a combination of metabolomics, stable isotope analysis (fluxomics) and molecular interventions such as enzyme inhibitors and RNAi. In addition, to test the validity of mechanistic changes detected in the mouse to human metabolism we will investigate responses in cultured human primary cells. This proposal will both further define a pharmacological system of great relevance to the regulation of human nutrition and obesity, and provide a poly-omic dataset suitable for others to explore and develop tools for systems biology in adipose tissue.</gtr:technicalSummary><gtr:potentialImpactText>Understanding the roles of the PPARs in regulating energy balance, nutritional status and health has been a highly active area in many pharmaceutical companies both in the UK and across the globe. A number of agonists have been developed to target PPAR-alpha, PPAR-gamma or all three PPARs in order to treat type II diabetes and obesity. To illustrate this, the global sales of three PPAR agonists are listed: The PPAR-gamma agonists Rosiglitazone and pioglitazone have combined 2007 sales of about US$ 6.6 billion. The PPAR alpha agonist fenofibrate from Solvay Pharmaceuticals and Abbott yielded 2007 sales of US$ 1.9 billion. Thus, a better understanding of how PPAR-delta exerts its action may help in the development of new blockbuster drugs. Furthermore, the PPAR agonists are not without unwanted side-effects and safety concerns, at least from animal studies, and by identifying the consequences of chronic stimulation of the receptors one may be able to identify targets downstream of the PPARs which produce the beneficial effects on health without the unwanted side-effects. To ensure our research will be of relevance to the pharmaceutical industry we will continue a close collaboration between Drs Andy Nicholls and John Haselden at GlaxoSmithKline (see letter of support). This collaboration has already produced two project grants and two PhD studentships for the Griffin group. Understanding the regulation of energy balance will have benefit to the public in the UK. As stated in the application the UK is experiencing dramatic increases in obesity and the diseases it causes. This is affecting both the young and old and will have a significant health burden on the National Health Service in the future, as well as the capabilities of the UK's work force. Better understanding of how PPAR-delta upregulates beta-oxidation in adipose tissue will allow the development of drug, and even possibly nutritional interventions to stimulate the receptor. To ensure our work benefits the wider scientific community we will ensure that our results are published as manuscripts, and these, where possible, are open access. In addition Dr. Griffin has been involved in a number of schemes aimed at disseminating the results of his research to the public. This includes the 'Head Start' scheme for 17 year old scientists and the Princes Teaching Institute for school teachers. He has also appeared on BBC Radio 4's Material World discussing his research. The UK has a proud record in the development of mass spectrometry and one aspect of this proposal is the collaboration with Waters to improve structure identification in lipidomics. Although Waters is an international company it has a significant research base in Manchester (formerly Micromass). Our collaboration will help the company develop new solutions for lipidomics, particularly in software tools for interpreting the vast multivariate data produced. The project will also provide training in areas relevant to analytical biochemistry, safety assessment and drug efficacy, skills that are in demand in both academia and industry. This is important for the future of 'UK plc' as the major attraction of pharmaceutical and biotechnology companies to this country is the highly skilled work force found in the UK.</gtr:potentialImpactText><gtr:fund><gtr:end>2011-09-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/2512EF1C-401B-4222-9869-A770D4C5FAC7"><gtr:id>2512EF1C-401B-4222-9869-A770D4C5FAC7</gtr:id><gtr:name>BBSRC</gtr:name></gtr:funder><gtr:start>2010-07-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>504644</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>2nd Metabolomics Sardinian Scientific School</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>C9A1E726-F157-40D6-B1DA-41E3F102EA0A</gtr:id><gtr:impact>2nd Metabolomics Sardinian Scientific School was aimed at post-grad students new to the field of metabolomics. We gave seminars and workshops in various tools and techniques in metabolomics.</gtr:impact><gtr:outcomeId>58be91ffd0e376.17281807</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Work experience for two school boys</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>7015F510-DD7F-45A3-8E5A-D64C9224EFD7</gtr:id><gtr:impact>Work experience for two school boys: two school boys spent a week in my lab following members around to get some experience of what its like being a scientist.</gtr:impact><gtr:outcomeId>58be9ca3c4fbb4.99465167</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Cambridge Science Week 2017</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>A2A63695-68E3-4D74-9721-0031FCE0C4D9</gtr:id><gtr:impact>took part in Cambridge Science week and put on a display on personalised medicine and health using advanced biochemical techniques.</gtr:impact><gtr:outcomeId>58c6c9ae213365.21891236</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2017</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>40000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Astra Zeneca CASE studentship</gtr:description><gtr:end>2019-09-02</gtr:end><gtr:fundingOrg>AstraZeneca</gtr:fundingOrg><gtr:id>F1903067-E12B-472A-AC5A-D116E2E8702C</gtr:id><gtr:outcomeId>58beaca44e25d0.84768316</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2016-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>417000</gtr:amountPounds><gtr:country>Global</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>GSK-Astra Zeneca partnership awards</gtr:description><gtr:end>2020-03-02</gtr:end><gtr:fundingOrg>GlaxoSmithKline (GSK)</gtr:fundingOrg><gtr:id>0B59A037-8E0E-4079-A6EC-0A576419CD30</gtr:id><gtr:outcomeId>58c6cb9b7e9075.35425051</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2017-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>124000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Technology Development Grant, MetaboFlow - the development of standardised workflows for processing metabolomics data to aid reproducible data sharing and big data initiatives</gtr:description><gtr:end>2019-11-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:fundingRef>202952/B/16/Z</gtr:fundingRef><gtr:id>06FF5269-CD7E-4D5B-B94D-D6A794FB621E</gtr:id><gtr:outcomeId>58c6c5f430db06.11331108</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-12-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>100000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>MedImmune Cambridge</gtr:department><gtr:description>Medimmune industrial studentship</gtr:description><gtr:end>2019-09-02</gtr:end><gtr:fundingOrg>MedImmune</gtr:fundingOrg><gtr:id>9FE34376-E323-4F0B-BB5D-781489F27392</gtr:id><gtr:outcomeId>58beba775feb94.63297316</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2016-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs><gtr:impactSummaryOutput><gtr:description>We have continued to collaborate with GSK in both general drug safety assessment and also in the area of ppar agonists.
We have initiated a collaboration with Medimmune to investigate browning in white adipose tissue.</gtr:description><gtr:firstYearOfImpact>2012</gtr:firstYearOfImpact><gtr:id>8CB39E08-6F22-455E-A985-C4EA567B4A76</gtr:id><gtr:impactTypes/><gtr:outcomeId>56dace06a0d7a6.66225230</gtr:outcomeId><gtr:sector>Healthcare,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:impactSummaryOutput></gtr:impactSummaryOutputs><gtr:intellectualPropertyOutputs/><gtr:keyFindingsOutput><gtr:description>We discovered that an important anti-diabetes drugs, called PPAR delta agonists, not only increase fatty acid metabolism in muscle but also do this in the fat cells (white adipose tissue). This has led us to investigate other mechanisms that increase fatty acid oxidation in fat cells and we have recently published a paper describing how a simple dietary modification increases fatty acid oxidation in fat in mice and rats. We are currently investigating whether this mechanism extends to humans as an anti-obesity treatment.</gtr:description><gtr:exploitationPathways>We are currently investigating whether this mechanism extends to humans as an anti-obesity treatment.</gtr:exploitationPathways><gtr:id>D69D8FCE-C217-4CF1-85C6-F0FBAA2311A3</gtr:id><gtr:outcomeId>56dacd131c9b41.32826249</gtr:outcomeId><gtr:sectors><gtr:sector>Agriculture, Food and Drink,Healthcare,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:sectors></gtr:keyFindingsOutput><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>SACN advisory committee on dietary fats</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>BDC17BD3-0E26-4A2A-9A59-25D750F0C234</gtr:id><gtr:outcomeId>56dac24a0bd645.44993539</gtr:outcomeId><gtr:type>Participation in a advisory committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>AD0DAC8A-01A4-4DD3-A5BF-17476BCBFDC6</gtr:id><gtr:title>Methods for performing lipidomics in white adipose tissue.</gtr:title><gtr:parentPublicationTitle>Methods in enzymology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/59b6e3728c2503ea027017abe00a44c7"><gtr:id>59b6e3728c2503ea027017abe00a44c7</gtr:id><gtr:otherNames>Roberts LD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:isbn>9780128002803</gtr:isbn><gtr:issn>0076-6879</gtr:issn><gtr:outcomeId>pm_53cc044c044e8b5c8</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1EE89C55-9DE6-47DC-9E4F-4E3E31006771</gtr:id><gtr:title>The contrasting roles of PPARd and PPAR? in regulating the metabolic switch between oxidation and storage of fats in white adipose tissue.</gtr:title><gtr:parentPublicationTitle>Genome biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/59b6e3728c2503ea027017abe00a44c7"><gtr:id>59b6e3728c2503ea027017abe00a44c7</gtr:id><gtr:otherNames>Roberts LD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1474-7596</gtr:issn><gtr:outcomeId>pm_5435afd5afdedec6b</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BA642AFE-3174-4C92-8EAB-88BB0B2ABB79</gtr:id><gtr:title>A new role for lipocalin prostaglandin d synthase in the regulation of brown adipose tissue substrate utilization.</gtr:title><gtr:parentPublicationTitle>Diabetes</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e137cbde914442352a009c77419799ba"><gtr:id>e137cbde914442352a009c77419799ba</gtr:id><gtr:otherNames>Virtue S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0012-1797</gtr:issn><gtr:outcomeId>pm_13207_27_22923471</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>49B3B416-6D92-4F9C-B6FD-27B823B01376</gtr:id><gtr:title>Applications of metabolomics for understanding the action of peroxisome proliferator-activated receptors (PPARs) in diabetes, obesity and cancer.</gtr:title><gtr:parentPublicationTitle>Genome medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/605afa4d43c7798be6ab908c49549eb0"><gtr:id>605afa4d43c7798be6ab908c49549eb0</gtr:id><gtr:otherNames>Ament Z</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1756-994X</gtr:issn><gtr:outcomeId>pm_13207_27_22546357</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1AE94E97-E733-4C8C-AA36-3CAC44D2A7F9</gtr:id><gtr:title>Prostaglandin profiling reveals a role for haematopoietic prostaglandin D synthase in adipose tissue macrophage polarisation in mice and humans.</gtr:title><gtr:parentPublicationTitle>International journal of obesity (2005)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e137cbde914442352a009c77419799ba"><gtr:id>e137cbde914442352a009c77419799ba</gtr:id><gtr:otherNames>Virtue S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0307-0565</gtr:issn><gtr:outcomeId>56bb67e7a96589.82505349</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AA9ED729-0D58-4563-8F95-326E6C01AE3A</gtr:id><gtr:title>A metabolomics investigation of non-genotoxic carcinogenicity in the rat.</gtr:title><gtr:parentPublicationTitle>Journal of proteome research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/605afa4d43c7798be6ab908c49549eb0"><gtr:id>605afa4d43c7798be6ab908c49549eb0</gtr:id><gtr:otherNames>Ament Z</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1535-3893</gtr:issn><gtr:outcomeId>doi_55f94d94d0a45225</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>23EE1E53-83D9-42D0-AB62-A52E71591641</gtr:id><gtr:title>PPAR-pan activation induces hepatic oxidative stress and lipidomic remodelling.</gtr:title><gtr:parentPublicationTitle>Free radical biology &amp; medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/605afa4d43c7798be6ab908c49549eb0"><gtr:id>605afa4d43c7798be6ab908c49549eb0</gtr:id><gtr:otherNames>Ament Z</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0891-5849</gtr:issn><gtr:outcomeId>56bb5ecc443a80.79856525</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E9F42B0C-2A07-401A-8BD9-A3FDD35A791B</gtr:id><gtr:title>Hematopoietic IKBKE limits the chronicity of inflammasome priming and metaflammation.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d6013e7c1934b6d55026ed02e21ab0c8"><gtr:id>d6013e7c1934b6d55026ed02e21ab0c8</gtr:id><gtr:otherNames>Patel MN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>56bb67e8467268.42426177</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6583C035-B9E6-4E42-A695-6EE09C26B0EF</gtr:id><gtr:title>Suppression of erythropoiesis by dietary nitrate.</gtr:title><gtr:parentPublicationTitle>FASEB journal : official publication of the Federation of American Societies for Experimental Biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/22ed715a0fd2d6b6675acaed09c2c5c8"><gtr:id>22ed715a0fd2d6b6675acaed09c2c5c8</gtr:id><gtr:otherNames>Ashmore T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0892-6638</gtr:issn><gtr:outcomeId>56bb67e881b882.72131980</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BB3D6C1B-4160-4659-9C1E-33A7E36F3B7A</gtr:id><gtr:title>Response to Comment on Lee et al. Diabetes 2015;64:2836-2846. Comment on Roberts et al. Diabetes 2015;64:471-484.</gtr:title><gtr:parentPublicationTitle>Diabetes</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/59b6e3728c2503ea027017abe00a44c7"><gtr:id>59b6e3728c2503ea027017abe00a44c7</gtr:id><gtr:otherNames>Roberts LD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0012-1797</gtr:issn><gtr:outcomeId>56dad0d2b395b9.10848849</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0AB85E14-0307-4365-9F7B-87374982A6C4</gtr:id><gtr:title>Mechanistic insights revealed by lipid profiling in monogenic insulin resistance syndromes.</gtr:title><gtr:parentPublicationTitle>Genome medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dbf95ec29a8570e7cba45b6531f6cb39"><gtr:id>dbf95ec29a8570e7cba45b6531f6cb39</gtr:id><gtr:otherNames>Eiden M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1756-994X</gtr:issn><gtr:outcomeId>5675ea317920f</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>990869D5-7258-4FF7-87E9-5CFED1F38B30</gtr:id><gtr:title>Obesity in mice with adipocyte-specific deletion of clock component Arntl.</gtr:title><gtr:parentPublicationTitle>Nature medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/31cd347f1788091e7e6d2fe14ea9eec4"><gtr:id>31cd347f1788091e7e6d2fe14ea9eec4</gtr:id><gtr:otherNames>Paschos GK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1078-8956</gtr:issn><gtr:outcomeId>pm_13207_27_23142819</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>40FE75BE-3015-4528-A19A-382B7407979E</gtr:id><gtr:title>Lipocalin prostaglandin D synthase and PPAR?2 coordinate to regulate carbohydrate and lipid metabolism in vivo.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e137cbde914442352a009c77419799ba"><gtr:id>e137cbde914442352a009c77419799ba</gtr:id><gtr:otherNames>Virtue S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_13207_27_22792179</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>90C6B841-8C66-458B-AE92-AE11E08B9C90</gtr:id><gtr:title>Nutritional Ketosis Alters Fuel Preference and Thereby Endurance Performance in Athletes.</gtr:title><gtr:parentPublicationTitle>Cell metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/67be2475aac9535fc2f1fb52d61463db"><gtr:id>67be2475aac9535fc2f1fb52d61463db</gtr:id><gtr:otherNames>Cox PJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1550-4131</gtr:issn><gtr:outcomeId>58bd343ea469f8.47801649</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DB1C2145-0FFD-4224-B223-605E0CEA2B8D</gtr:id><gtr:title>A Metadata description of the data in &amp;quot;A metabolomic comparison of urinary changes in type 2 diabetes in mouse, rat, and human.&amp;quot;.</gtr:title><gtr:parentPublicationTitle>BMC research notes</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d0fa52afc678c4e6d52598c663a0af7a"><gtr:id>d0fa52afc678c4e6d52598c663a0af7a</gtr:id><gtr:otherNames>Griffin JL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1756-0500</gtr:issn><gtr:outcomeId>D8NBrRHYNi5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>62CA8C45-1478-427B-B698-993C95279568</gtr:id><gtr:title>Metabolomics as a tool for cardiac research.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Cardiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d0fa52afc678c4e6d52598c663a0af7a"><gtr:id>d0fa52afc678c4e6d52598c663a0af7a</gtr:id><gtr:otherNames>Griffin JL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1759-5002</gtr:issn><gtr:outcomeId>pm_5435afd5afde2db27</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B38C9923-1A28-4BAC-AE4D-BF54B447A4A7</gtr:id><gtr:title>Application of a Bayesian deconvolution approach for high-resolution (1)H NMR spectra to assessing the metabolic effects of acute phenobarbital exposure in liver tissue.</gtr:title><gtr:parentPublicationTitle>Analytical chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/70d89a409d011d93f733421534a3bee7"><gtr:id>70d89a409d011d93f733421534a3bee7</gtr:id><gtr:otherNames>Rubtsov DV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0003-2700</gtr:issn><gtr:outcomeId>546151c730abf5.96847732</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>36832AF8-C16F-49D0-8517-5643BA2DBA22</gtr:id><gtr:title>Adipose tissue fatty acid chain length and mono-unsaturation increases with obesity and insulin resistance.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/21cb25ff8772b4c914687a805b1d4c64"><gtr:id>21cb25ff8772b4c914687a805b1d4c64</gtr:id><gtr:otherNames>Yew Tan C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>56bb5ecbc0e064.89752787</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5EF16B61-9542-4B45-B8F2-71DBB05A4A70</gtr:id><gtr:title>Brown Adipose Tissue Thermogenic Capacity Is Regulated by Elovl6.</gtr:title><gtr:parentPublicationTitle>Cell reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5b0fe1561e92f157420919eb81c6a910"><gtr:id>5b0fe1561e92f157420919eb81c6a910</gtr:id><gtr:otherNames>Tan CY</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>56bb67e5619e62.67929974</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>28805726-1914-4F5A-AC1A-56A327C3B19B</gtr:id><gtr:title>Erratum: Adipose tissue fatty acid chain length and mono-unsaturation increases with obesity and insulin resistance.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5b0fe1561e92f157420919eb81c6a910"><gtr:id>5b0fe1561e92f157420919eb81c6a910</gtr:id><gtr:otherNames>Tan CY</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>58bd343f1d6077.99147528</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7AA37CA5-24B7-45BC-8665-45F771024303</gtr:id><gtr:title>Adaptive changes of the Insig1/SREBP1/SCD1 set point help adipose tissue to cope with increased storage demands of obesity.</gtr:title><gtr:parentPublicationTitle>Diabetes</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f3098d46384b300a0dd4b590e33f76cd"><gtr:id>f3098d46384b300a0dd4b590e33f76cd</gtr:id><gtr:otherNames>Carobbio S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0012-1797</gtr:issn><gtr:outcomeId>pm_13207_27_23919961</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0142272D-CAF7-4739-B764-65EDF68051EE</gtr:id><gtr:title>Methods of Adipose Tissue Biology: Methods of Adipose Tissue Biology: Part B</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/22d38b79efe9178f2b9cd9e0a50000fe"><gtr:id>22d38b79efe9178f2b9cd9e0a50000fe</gtr:id><gtr:otherNames>MacDougald, Ormond</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:isbn>9780128002803</gtr:isbn><gtr:outcomeId>i-5635886542.1599583bb54cb8</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>28F9B97C-1575-4E56-9B65-C28DB3A32B84</gtr:id><gtr:title>Lipidomics Profiling of Human Adipose Tissue Identifies a Pattern of Lipids Associated with Fish Oil Supplementation.</gtr:title><gtr:parentPublicationTitle>Journal of proteome research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/20eb75875233be60137d23bb1ac0c01c"><gtr:id>20eb75875233be60137d23bb1ac0c01c</gtr:id><gtr:otherNames>Stanley EG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1535-3893</gtr:issn><gtr:outcomeId>5a2fcff028d460.76924217</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>896B3A8F-2FF3-4559-97F5-9D697F23E5C5</gtr:id><gtr:title>Novel ketone diet enhances physical and cognitive performance.</gtr:title><gtr:parentPublicationTitle>FASEB journal : official publication of the Federation of American Societies for Experimental Biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ac60c126dd05fe5ce69dfda4816f4de9"><gtr:id>ac60c126dd05fe5ce69dfda4816f4de9</gtr:id><gtr:otherNames>Murray AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0892-6638</gtr:issn><gtr:outcomeId>58bd343e5b1e88.95303624</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>60BCE541-4EA6-400C-ADED-70F3C5625F04</gtr:id><gtr:title>The study of mammalian metabolism through NMR-based metabolomics.</gtr:title><gtr:parentPublicationTitle>Methods in enzymology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3d92cf36c0bdb3d82360a12275653cef"><gtr:id>3d92cf36c0bdb3d82360a12275653cef</gtr:id><gtr:otherNames>Salek R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0076-6879</gtr:issn><gtr:outcomeId>56758fac1c3b9</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">BB/H013539/1</gtr:identifier></gtr:identifiers><gtr:projectHierarchy><gtr:parents><gtr:parent><gtr:id>DECBA19C-8EC0-42AB-A871-82435C388F46</gtr:id><gtr:grantRef>BB/H013539/1</gtr:grantRef><gtr:amount>504644.03</gtr:amount><gtr:start>2010-07-01</gtr:start><gtr:end>2011-09-30</gtr:end><gtr:children><gtr:child rel="Transfer"><gtr:id>52405730-6906-4BDD-B9FC-FEB8E6C97E84</gtr:id><gtr:grantRef>BB/H013539/2</gtr:grantRef><gtr:amount>363926.53</gtr:amount><gtr:start>2012-03-31</gtr:start><gtr:end>2013-12-30</gtr:end><gtr:children/></gtr:child></gtr:children></gtr:parent></gtr:parents></gtr:projectHierarchy><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>